Pharmaceutical German drug major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen, have received marketing authorization from the European Commission for the oral multi-kinase inhibitor Nexavar (sorafenib) for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine. 30 May 2014